Novartis breast cancer drug Kisqali wins European panel backing
ZURICH (Reuters) - A European Medicines Agency (EMA) panel recommended on Friday approving Novartis's Kisqali drug, bolstering the Swiss drugmaker's bid to challenge rival Pfizer's Ibrance against tough-to-treat breast cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | European Medicines Agency (EMA) | Health | Pfizer